{"id":"W3188472626","doi":"10.1158/1078-0432.ccr-21-1497","title":"Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"Pharmacyclics","keywords":"Ibrutinib; Medicine; Rituximab; Waldenstrom macroglobulinemia; Internal medicine; Macroglobulinemia; Refractory (planetary science); Gastroenterology; Phases of clinical research; Progression-free survival; Neutropenia; Response Evaluation Criteria in Solid Tumors; Surgery; Clinical trial; Oncology; Lymphoma; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005625185,0.0006688474,0.001436158,0.0002512062,0.0003574276,0.001076917,0.0006063267,0.0007027843,0.001444294],"category_scores_gemma":[0.00202448,0.000250322,0.001679377,0.0004445354,0.0003463647,0.0005156236,0.0003828813,0.001555304,0.0004185812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007447831,"about_ca_system_score_gemma":0.0009430161,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007493871,"about_ca_topic_score_gemma":0.003337632,"domain_scores_codex":[0.9986765,0.0008246642,0.00009306378,0.0001289596,0.0001494013,0.0001273279],"domain_scores_gemma":[0.998694,0.000286253,0.0003842703,0.000178746,0.0001607278,0.0002960099],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6706002,0.007611079,0.06644964,0.00361442,0.02297061,0.0003385618,0.0005515853,0.002584694,0.03077484,0.0005419357,0.01870956,0.1752528],"study_design_scores_gemma":[0.5500972,0.1348868,0.2569408,0.0005707477,0.01967791,0.0012064,0.0002478639,0.002527481,0.009607392,0.0006406596,0.02347837,0.0001182379],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9723747,0.01751007,0.0009978818,0.0007612505,0.0001804634,0.001618938,0.003323054,0.00008048309,0.003153119],"genre_scores_gemma":[0.9858938,0.003251808,0.001180453,0.0007310769,0.0002077101,0.001234211,0.006712707,0.000028693,0.0007595319],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005625185,"threshold_uncertainty_score":0.02974921,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4036895078357418,"score_gpt":0.5643537866182178,"score_spread":0.160664278782476,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}